)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ABVC BioPharma
ABVC BioPharma (ABVC) investor relations material
ABVC BioPharma Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary29 Sep, 2026
Executive summary
Special meeting scheduled for October 28, 2026, to be held virtually for shareholder participation and efficiency.
Three key proposals: approval of a new equity incentive plan, ratification of recent equity awards, and authorization for potential share issuance for property acquisition in Taiwan.
Board unanimously recommends voting in favor of all proposals.
Record date for voting is September 14, 2026, with 26,694,476 shares outstanding.
Voting matters and shareholder proposals
Proposal 1: Approve the 2026 Equity Incentive Plan, replacing the 2016 plan and introducing a new share reserve formula and evergreen provision.
Proposal 2: Ratify equity awards (600,000 shares) granted to two advisors between February 16 and September 11, 2026.
Proposal 3: Authorize issuance of up to 1,600,653 shares at no less than $1.00 per share for acquisition of land in Taoyuan and Hualien, Taiwan, in compliance with Nasdaq rules.
All proposals require a majority of votes cast for approval.
Board of directors and corporate governance
Board members, including Ms. Shuling Jiang, are involved in the proposed property transaction, triggering related-party review.
Audit Committee will review and approve the related-party transaction as per company and Nasdaq governance requirements.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ABVC BioPharma
- Shareholders to vote on new equity plan, equity award ratification, and share issuance for Taiwan land.ABVC
Proxy filing - Approval sought for new equity plan, equity award ratification, and share issuance for Taiwan land deal.ABVCProxy filing
- Shareholders will vote on a new equity plan, award ratification, and major share issuance for land acquisitions.ABVCProxy filing
- Net loss narrowed, no revenue generated, and going concern risks persist amid restructuring.ABVCQ2 2026
- Shareholders will vote on a new equity plan, equity award ratification, and share issuance for a Taiwan land deal.ABVCProxy filing
- Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit.ABVCQ1 2026
- Shareholders will vote on director re-elections, auditor ratification, and an equity plan increase.ABVCProxy Filing
- Net loss increased to $8.4M in 2025 with no revenue recognized and ongoing going concern risks.ABVCQ4 2025
- Shareholders will vote on director re-elections, auditor ratification, and an equity plan increase.ABVCProxy Filing
Next ABVC BioPharma earnings date
Q3 202616 Nov, 2026
ABVC BioPharma
Next ABVC BioPharma earnings date
Q3 202616 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ABVC BioPharma Inc. is a U.S.-based biotechnology company engaged in the research, development, and commercialization of pharmaceutical and medical device products. The company focuses on advancing drug candidates and therapies in areas such as oncology, central nervous system disorders, and ophthalmology. ABVC BioPharma leverages partnerships with research institutions and healthcare organizations to develop innovative treatment solutions. ABVC BioPharma Inc. is headquartered in Fremont, California, and its shares are listed on the Nasdaq Stock Market (NASDAQ).